Testing metformin and carvedilol for cirrhosis with variceal bleeding
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether adding metformin to carvedilol (a standard drug) lowers liver pressure more than carvedilol alone in people with cirrhosis who have had variceal bleeding. The goal is to prevent future bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cirrhosis and have had bleeding from enlarged veins in your food pipe (variceal bleed).
- You are between 18 and 75 years old.
- You have not taken metformin or certain heart medications (like carvedilol or other beta-blockers) in the last 5 days.
- You do not have severe liver failure (Child-Turcotte-Pugh score of 12 or higher).
- Your bilirubin (a liver marker) is not above 3 mg/dl, and your creatinine (a kidney marker) is not above 1.5 mg/dl.
- You do not have certain conditions like a very slow heart rate, low blood pressure, asthma, heart failure, blood clots in the liver, liver cancer, or severe confusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a second drug (midodrine) to the standard drug (carvedilol) is better at preventing another bleeding episode from varices in people with cirrhosis. It aims to reduce the risk of early re-bleeding and improve outcomes.
This trial tests whether the blood thinner apixaban can help prevent early-stage cirrhosis from worsening. You may be eligible if you have compensated (stable) cirrhosis due to alcohol and have signs of portal hypertension.
This trial tests whether adding a statin (simvastatin) to the usual heart medication carvedilol helps people with both cirrhosis and a related heart problem live longer and avoid serious liver complications.
This study compares two ways to prevent bleeding from enlarged veins in the esophagus (varices) in people with liver cancer and cirrhosis. One method uses a medication called carvedilol alone, while the other combines carvedilol with a procedure called band ligation, which ties off the veins to prevent bleeding.
This trial tests whether carvedilol can prevent the first development of swollen veins (varices) in the esophagus in people with cirrhosis who do not have them yet. It may help lower the risk of future bleeding from those veins.
This trial tests two heart medications, carvedilol and empagliflozin, to see if they improve heart function in people with cirrhosis (liver scarring). It might help those who have early signs of heart stiffness but normal pumping strength.
Hear when a new Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.